[
    [
        {
            "time": "",
            "original_text": "康泰生物现1笔大宗交易 ，共成交16,323.84万元",
            "features": {
                "keywords": [
                    "康泰生物",
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物现1笔大宗交易 ，共成交16,323.84万元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "抗击新冠疫情影响系列报告之五：新冠疫苗研发跟踪 需求与成本分析",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "研发",
                    "需求",
                    "成本分析"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "抗击新冠疫情影响系列报告之五：新冠疫苗研发跟踪 需求与成本分析",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【医药】阿斯利康新冠疫苗达到主要功效终点，医药进入配置阶段——医药行业周报——中性",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "新冠疫苗",
                    "主要功效",
                    "医药行业",
                    "配置阶段"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】阿斯利康新冠疫苗达到主要功效终点，医药进入配置阶段——医药行业周报——中性",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]